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Abstract
We model the interaction between the immune system and
tumor cells including a time delay to simulate the time
needed by the latter to develop a chemical and cell me-
diated response to the presence of the tumor. The results
are compared with those of a previous paper, concluding
that the delay introduces new instabilities in the system
leading to an uncontrolable growth of the tumour. Then
a cytokine based periodic immunotherapy treatment is in-
cluded in the model and the effects of its dossage are stud-
ied for the case of a weak immune system and a grow-
ing tumour. We find the existence of metastable states
(that may last for tens of years) induced by the treatment,
and also of potentially adverse effects of the dossage fre-
quency on the stabilization of the tumour. These two ef-
fects depend on the delay, the cytokine dose burden and
other parameters considered in the model.
Keywords tumor growth, delay differential equations,
immunotherapy, immunodepression
1 Introduction
Immunotherapy is defined as the use of the immune sys-
tem and its products to prevent, treat and control some
illness. Immunotherapy may act stimulating the immune
system of a patient with some kind of melanoma, kidney
cancer, etc. . . in order to eliminate or control the popula-
tion of tumoral cells.
The development of a cancer tumor under the influence
of the immune system deploys a very rich dynamics with
some aspects that must be highlighted:
1. T-lymphocytes are the cells that perform the tumor
elimination, but to do that, another cells, the B- lym-
phocytes, must activate them with the help of cy-
tokines [1, 2, 3]
2. When the tumor size increases, it induces a deactiva-
tion of lymphocytes that enter the tumor region. This
phenomenon is known as immunodepression
3. Obviously, in the whole process of interaction be-
tween the immune system and the tumor, a delay be-
tween the detection of the “strange cells” (antigen)
and the attack of the T-lymphocytes is present. This
delay will be considered as the control parameter in
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the system under study [4, 5]. As we shall see, it is
important since it produces changes in the stability
of the solutions of the set of equations describing the
system.
In this paper, the model proposed in [6] is modified with
the inclusion of a “memory effect” in the term describ-
ing the interaction between the immune system and the
tumor. This leads to formulate the problem in terms of a
set of delay differential equations [7, 8, 9]. The influence
of this memory effect is studied both with and without
therapy. Besides, the range of variation of the biologic
parameters is estimated, so that the numeric simulations
were performed inside the range.
As far as we know, the existence of a delay between the
stimulus (antigen) and the triggering of the defenses of
the immune system has not been considered enough in the
literature, despite the excellent reports in [10, 11], where
the effect of time delay in the dynamics of tumor- immune
system is included in the model proposed in [12]. There,
it is shown that time delay is a very important factor to
take into account in the modelling of the immune system
and the reaction of living organisms to diseases. Another
delay times have been shown to be of importance. For
example, in [13] this characteristic time is introduced in a
model adapted from [12, 14] to take into account the cell
cycle, leading to a linear delayed term in the equations.
In the same way, the study presented in the this paper is
based on the model introduced by some of the authors in
[6] to describe the effects of tumor immunodepression,
now including a time characterising the immune system
delayed response to the tumor.
2 The model
2.1 Construction of the model
In [6], a Lotka-Volterra model with the inclusion of some
additional terms was proposed as:
dX
dt = aX− bXY
dY
dt = dXY − fY − kX + u+F cos2 wt
(1)
where X(t), and Y (t) are the populations of tumor cells
and T-lymphocytes, respectively. The growing rate of tu-
mor cells is proportional to X and the mortality rate is pro-
portional to the frequency of interaction with the lympho-
cytes. The growing rate of lymphocytes is proportional
to the interaction with the tumor cells and to the flux rate
(u) of lymphocytes to the region where the tumor is local-
ized. Their death rate is linked in this model to two terms:
natural death (− fY ) and the increase of the tumor mass,
which may induce a depression of the immunity system
(−kX). A characteristic of this system is that the immun-
odepression has been taken into account. Immunodepres-
sion may lead to fatal consequences since it may annihi-
late the whole immune system, mathematically expressed
as Y (t) = 0. (In this model, the population of lympho-
cytes may even become negative after being null, so that
in that case it makes no sense to follow the integration).
To introduce the effects produced by the periodic therapy
with cytokines we choose, as in [6], the term F cos2 wt, as
a first model of a periodic positive function, being w the
frequency of the therapy and F the peak value of the dose.
The term dXY is specially important for this study.
It mimics the interaction between the two populations,
X and Y , with a frequency d of recognition of malig-
nant cells by the immune system. We consider the effect
of time delay for this chemical signal mediated interac-
tion which, according to [10], introduces here the values
X(t −T ) and Y (t − T ). The evolution equations (1) be-
come now:
dX
dt = aX− bXY
dY
dt = dX(t−T )Y (t−T )− fY − kX + u+G(t)
(2)
where G(t) = F cos2 wt, and T is the time the immune
system takes to react over the malignant cells once recog-
nized. We want to point out that the delay time is absent
in the other interaction term bXY , since it represents the
direct action of the already present T-lymphocytes and,
therefore, it already exist at time t.
If F = k = u = 0, we recover the classical delayed
Lotka-Volterra model [15] with characteristic time tc =
1/
√
a f . This time will be used to rescale the system (2)
as:
dx
dt˜ = αx− xy
dy
dt˜ = x(t˜− τ)y(t˜− τ)− 1α y−κx+σ+H(t˜)
(3)
being
H(t˜) =V cos2 βt˜
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where
t˜ = t/tc, τ = T/tc, x =
d√
a f X , y =
b√
a f Y
and
κ =
kb
d
√
a f , α =
√
a
f , σ =
ub
a f
V =
Fb
a f , β =
w√
a f
To simplify notation, from now on we make t˜ = t.
2.2 Estimation of some parameters
To get some insight about the numerical range of the pa-
rameters to include in the model, let us estimate the values
of the parameters a, f , T , u, b, d, k as well as X0, using
days as time unit.
It is known that the time a solid tumor takes to reach
twice its initial volume is about 70 days [16]. Obviously,
this “representative” value is useful only to have an idea
of the orders of magnitude; there are tumors that dupli-
cate their volume in 20 days, whereas others can do it in
100 days. Tumors like those of colon or rectal cancer take
a few years to duplicate. We admit that in the absence
of lymphocytes the growth is exponential so our param-
eter a = log2/Td (days)−1 will be bounded to the inter-
val a ∈ [10−4, 10−2] days−1. This is a conservative esti-
mation, compared to others found in the literature [17].
Experimentally, the values for the lifetime of lympho-
cytes can be measured, being about 30 days [12]. Then
it can be assumed that f ∈ [10−2, 10−1] days−1. The
time the lymphocytes take to proliferate is between 2 and
12 days [11]. This time can be taken as the delay time
T of the immune system. Assuming that, in the absence
of tumor, there is an already established stationary state,
the second equation in (2) shows that in the initial state:
u− fY = 0. It is known that in the spleen of a labo-
ratory rat there are approximately 108 lymphocytes, but
only part of them are cytotoxic T-lymphocytes. Let us
cautiously evaluate this fraction as about 3% [4, 6, 10], so
that Y0 ≃ 3 ·105 cells. With these data it can be estimated
that u≃ 1.2 ·104 cells ·day−1. As in [12, 14], other param-
eters can be guessed so that b ∈ [10−9, 10−7] cells−1, and
d is then of the same order as b and with the same dimen-
sions. Besides, considering that k represents the fraction
of tumor cells that block the flow of lymphocytes to the
region occupied by the tumor, it can be assumed the ex-
istence of a initial population X0 of about 106 cells and,
in the absence of lymphocytes, we can make an initial ap-
preciation of k ≃ 1.2 · 10−2 days. All these estimates are
in good agreement with particular values collected in the
literature (see [17] and references therein).
These estimates of the parameters in (3), are shown in
table 1.
min max typical
α ∼ 10−2 ∼ 1 1.5
κ ∼ 10−2 ∼ 10 0.95
σ ∼ 10−2 ∼ 103 0.5
τ ∼ 10−3 ∼ 102 ∼ 1
x0 ∼ 10−3 ∼ 102 0.1
Table 1: Ranges for the orders of magnitude of the di-
mensionless parameter values of equation (3) as well as
initial condition for tumour cell population. In the last
column, typical values used in the simulations reported in
this work.
3 Results
3.1 System with G(t) = 0 and without delay
(from [6])
Our system (3) without delay and with G(t) = 0 becomes:
dx
dt = αx− xy
dy
dt = xy− 1α y−κx+σ
(4)
The stability of the stationary states of this system can be
expressed as:
1. State L0 = (0, ασ), tumorless state
If σ > 1 ⇒ Stable node
If σ < 1 ⇒ Saddle point (E1)
2. State L1 =
( 1−σ
α−κ , α
)
If κα > σ > 1 or σ >
κ
α > 1 ⇒Saddle point (E2)
If κα < σ < 1 ⇒ Stable node or focus (E3)
If σ < κα < 1 ⇒Unstable node or focus (E4)
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3.2 Delayed system without treatment
(G(t) = 0)
In this case our system becomes:
dx
dt = αx− xy
dy
dt = x(t− τ)y(t− τ)− 1α y−κx+σ
(5)
Current techniques of delay differential equations give the
following analytic results concerning stability of solutions
[7, 8, 9]:
1. The stability of the tumorless state L0 is unaltered.
Then (E1) is fulfilled ∀τ≥ 0
2. The state L1 is kept unstable ∀τ≥ 0 in all cases given
by (E2).
3. In the stability range given by (E3), a value of τ, i.e.
τc, exists such that the stationary state L1 becomes
unstable.
4. For the range given by (E4), the unstable state L1
preserves its instability.
 0
 0.05
 0.1
 0.15
 0.2
 0.25
 0.3
 0.35
 0.4
 0.45
 0.9  1  1.1  1.2  1.3  1.4  1.5  1.6  1.7  1.8  1.9
τc
α
Stability
Figure 1: Function τc(α), the threshold above which the
system (5) becomes unstable. Here the values of κ= 0.95,
σ = 0.5, within the physiological estimated range, were
taken such that the system is stable for τ = 0. No im-
munological treatment (V = 0) was considered.
The value of τ = τc for which L1 becomes destabilized
due to the presence of the delay can be computed analyti-
cally (see [7] for details, or the appendix in [13]). Figure
1 shows these values of τ for which the system becomes
unstable, as a function of the parameter α (the same can
be done applying the criteria in [7] for the other param-
eters κ and σ). These values of τc(α) can be computed
analytically within the range of parameters for which L1
has positive abscissa and where L1 is stable for τ = 0.
3.3 Results with delay and therapy
To make a useful phase diagram, numerical integration of
the system (3) can be performed for different values of the
parameters and explore the values of β and τ for which,
given a set of values of the other parameters, the system
becomes stable or unstable.
As the initial condition for the integration of the sys-
tem of delay differential equations, the steps method can
be used for which initial conditions need to be speci-
fied, giving the values of x(t) and y(t) in the interval
[−τ, 0). We will take as a realistic initial condition,
x(t) = x0(0)eα(1−σ)t , y(t) = ασ, in t ∈ [−τ, 0), corre-
sponding to an exponentially growing tumour, and an un-
aware immune system (τ-delayed response).
We will perform the numerical integration of the sys-
tem up to a time tmax corresponding to ∼ 25 years (from
typical values estimated in 2.2, it can be obtained tmax ∈
[30, 103]; we will consider tmax ≤ 100 in what follows)
. However, whenever the condition y ≤ 0 is met, that is,
when the immune system becomes anihilated due to tu-
mor agressiveness, integration will stop before t = tmax.
The result of the integration of (3) with these initial
conditions and this stop conditions (y > 0 and t < tmax),
quite surprisingly, leads to a division of the (β, τ) plane
into three regions instead of two as could be expected,
with an interesting “transition region” in which, being
the system unstable, the instability manifests itself only
“asymptotically”, i.e., only when a very long time has
elapsed.
The region marked as stable in figure 2 denotes that the
system remains stable at any “biologically meaningful”
time, that is, tumour growth is controlled by the cytokine
treatment. The one marked as unstable denotes, for the
chosen values of the parameters, those values of the fre-
quency β and the delay τ for which, the system becomes
unstable in a finite time (less than tmax) leading to an un-
limited tumor growth and total annihilation of the immune
system [6].
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Figure 2: Representation of stable and unstable regions
in the phase plane (β, τ). The values of the other pa-
rameters in this case are: κ = 0.95, σ = 0.5, α = 1.5,
V = 0.5, all of them within the estimated physiological
range. The initial conditions were thus taken as x0 = 0.1,
y0 = σα = 0.75. Dashed line delimits the asymptotically
stable region where tumour size remains controlled after
t = 100. Solid line limits the “marginally stable” region,
where tumor grows in an uncontrollable way after a di-
mensionless time tmax = 10.
The marginally stable region corresponds to unstable
states where instabilities manifest themselves after such
a long time (for t > tmax) that they have not a practical
sense. In the above case, inside this region the instabili-
ties manifest only for times in the order of tens of years,
an unpractical value in the medical sense. The limit be-
tween this marginally stable region and the unstable one
in figure 2, depends strongly on the initial conditions (x0,
y0 as well as on the hipotheses about their history) used
for the numerical calculation.
4 Discussion and Conclusions
We have studied the effect of the chemical signal and B-
lymphocytes mediated interaction between (T-)lympho-
cytes and cancer cells (that is, the time delay) upon the
development and growth of a cancer tumor. We have
found that an increase in this body reaction time will un-
stabilize a system in which the tumor has evolved to a
latent state. As far as this delay is a body characteristic
time, it will classify cancer situations into stable (that is,
limited by the immune system and thus curable) and un-
stable (those which cannot be controlled by the immune
system). These states will be characterized by the par-
ticular dynamical system parameter values, which must
be estimated as shown in section 2.2 from real available
data. Furthermore, the mathematical form of the evolu-
tion equations determines parameter combinations (in the
form of dimensionless groups) which are more suitable to
describe and classify the dynamics.
For a fixed time delay, numerical simulations show that
tumors evolve under cytokine treatment as follows. For
an initially unstable system, above the τc critical value,
immunotherapy treatment helps to stabilize this state. For
low dossage frequency β, tumor evolves so slowly that
the system behaves as stable for times larger than a given
tmax (taken of the order of decades, see conditions in 3.3).
Above a threshold the system becomes also asymptoti-
cally stable. Therapy does not lead to the full anihilation
of tumor cells, but keeps tumor size in a controlled state,
allowing the inclusion of other methods, like surgery, or
more directed therapies like radiation, aimed to a local-
ized and controlled tumoral mass.
Finally, when the system is not stable but instability
does not lead to uncontrolled tumor growth for, at least,
tmax (taken of the order of two decades), β dossage values
larger than a critical one may lead to system unstabiliza-
tion as well as to its stabilization if the frequency is fur-
ther increased, in a way sensitive to the initial state of the
tumour and the particular value of τ. In general, we con-
clude that there exist one critical low dossage frecuency
that makes the system unstable (for limited times smaller
than a tmax) and another higher frequency that takes the
system back to stability (long time stability, in this case).
These particular values will depend on the immune sys-
tem delay (τ), as well as on the dose burden (V ) and other
parameters of the system.
It is of paramount importance to notice that for some
practical range of citokine dossage frequencies (β & 0.75
in the particular case shown in figure 2), a particular value
of the immune system delay may fall above the region of
stability (asymptotic as well as transitory), making the use
of immunotherapy useless.
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